Interstitial Lung Disease a 'Manageable' Side Effect of Trastuzumab Deruxtecan
New data confirm a risk for interstitial lung disease (ILD) in women with HER2-positive metastatic breast cancer receiving the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) but show that most cases are mild and occur early.